Your email has been successfully added to our mailing list.

×
0 0.0436893203883494 0.213592233009709 0.37378640776699 0.407766990291262 0.210679611650486 0.0728155339805825 0.111650485436893
Stock impact report

Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meetin...

Akari Therapeutics Plc ADS (AKTX)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration (FDA): Part A dose confirmation study. Dosing scheme has been agreed with the FDA through Akari’s participation in the Model Informed Drug Development (MIDD) Program.Part B single arm responder-based efficacy study will follow an interim analysis of Part A and a meeting with the FDA. Phase III HSCT-TMA study expected to open by the end of Q4 2019.HSCT-TMA program has received both orphan and Fast Track designations from the FDA.New data from ongoing long-term PNH study shows that all six patients from the Phase II study who were transfusion dependent at entry are now transfusion independent on nomacopan. NEW YORK and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopha [Read more]
Impact snapshot Event time: AKTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
AKTX alerts
from News Quantified
Opt-in for
AKTX alerts

from News Quantified
Opt-in for
AKTX alerts

from News Quantified